跳至主要内容
临床试验/NCT02308098
NCT02308098已完成3 期

Study Comparing Bronchodilator Efficacy of Two Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler; a Randomised, Double-blind, Double-dummy, Multicentre, Single Dose, Crossover Study in Asthmatic Subjects

Orion Corporation, Orion Pharma1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
72
试验地点
1
主要终点
Average FEV1

研究概览

简要总结

The purpose of this study is to confirm equivalent bronchodilator efficacy of the test product compared to the reference product.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

Experimental

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

干预措施: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh (Drug)

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

Experimental

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

干预措施: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh (Drug)

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

Experimental

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

干预措施: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh (Drug)

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

Experimental

Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

干预措施: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh (Drug)

Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

Experimental

Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

干预措施: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh (Drug)

Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

Experimental

Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

干预措施: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh (Drug)

Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

Experimental

Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

干预措施: Symbicort Turbuhaler 320/9 ug/inhalation 1inh (Drug)

Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

Experimental

Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

干预措施: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh (Drug)

结局指标

主要结局

Average FEV1

时间窗: 12 h

FEV1 determined from serial spirometry and calculated on the basis of area under the curve

次要结局

  • Maximum FEV1(12 h)
  • FEV1 at 12 h(12 h)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验